ArticleAging and disease2025
Age-, Sex-, and Ancestry-Specific Prevalence of Hearing Loss in UK Biobank and All of Us Research Program.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genome-wide investigation highlights global and local pleiotropy linking neurodevelopmental disorders to acquired hearing problems.Psychological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hearing loss (HL) is a leading cause of global disease burden, but limited information is available regarding differences among individuals of diverse ancestral backgrounds. Here, we assessed age-, sex-, and ancestry-specific prevalence of HL in 827 406 participants from UK Biobank (UKB, N = 448 193) and All of Us Research Program (AoU, N = 379 213). HL was defined based on electronic health records and self-reported information, and HL prevalence was calculated for each subgroup. Age trends and prevalence differences between sexes and ancestries were tested. Age-standardized prevalence was computed for UKB and AoU using the combined sample size of the two cohorts as the standard population. The overall HL prevalence was 28% in UKB (24% in females; 34% in males) and 16% in AoU (13% in females; 20% in males). Sex differences were statistically significant across all age groups in UKB, and among participants aged >55 years in AoU. Across ancestry groups, males had a higher prevalence of HL than females, except for those of African descent in the AoU sample (10% in females and 9.5% in males). The ancestry-specific prevalence was highest among those of European descent in both UKB (29%) and AoU (20%), and lowest among those of African descent (12%) in UKB and Central/South Asian descent (7.3%) in AoU. The HL polygenic risk score was associated with HL in both female and male samples. Overall, this study provides comprehensive evidence that sex differences in HL prevalence should be considered in the context of population diversity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.